03:22 PM EST, 12/19/2025 (MT Newswires) -- Amgen ( AMGN ) is cutting prices on key medicines for US patients, aligning with the Trump administration's Most Favored Nation pricing goals.

The company will expand its AmgenNow direct-to-patient program to include migraine drug Aimovig and arthritis treatment Amjevita with each priced at $299 per month, almost 60% to 80% below current US list prices.

"The program is open to all eligible patients, including those who are uninsured, enrolled in high-deductible health plans or prefer to pay with cash or out of pocket," Amgen ( AMGN ) said Friday in a statement. The medicines, along with cholesterol drug Repatha, will also be offered through TrumpRx.gov.

Price: 328.03, Change: +3.61, Percent Change: +1.11